Extended Imatinib Therapy Slashes Recurrence Risk in High-Risk GIST Patients
Study shows 6 years of adjuvant imatinib significantly reduces relapse risk in high-risk GIST patients.
Subcutaneous Nivolumab: A Game-Changer for Advanced Kidney Cancer Treatment
Subcutaneous nivolumab proves noninferior to IV administration in advanced kidney cancer patients.
New Hope in Lung Cancer: Dostarlimab Rivals Pembrolizumab in First-Line Treatment
Phase II trial shows dostarlimab plus chemo matches pembrolizumab efficacy for metastatic NSCLC patients.
New Hope for Acute Myeloid Leukemia: Cusatuzumab Shows Promise in Clinical Trial
Cusatuzumab plus azacitidine shows efficacy in treating newly diagnosed acute myeloid leukemia
Latest
Extended Imatinib Therapy Slashes Recurrence Risk in High-Risk GIST Patients
Study shows 6 years of adjuvant imatinib significantly reduces relapse risk in high-risk GIST patients.
EMERALD-1 Trial: Immunotherapy Combo Boosts Survival in Liver Cancer
Adding durvalumab and bevacizumab to TACE improves progression-free survival in hepatocellular carcinoma.
High-Fiber Diet Trial Aims to Boost Immunotherapy Success in Melanoma Patients
New study explores how high-fiber diet affects gut microbiome and immune response in melanoma patients
Promising Results for Neoadjuvant Immunotherapy in Advanced Melanoma
Phase 1/2 trial shows high response rates for pembrolizumab-based neoadjuvant regimens in stage IIIB-D melanoma
DESTINY-Breast06 Trial: Trastuzumab Deruxtecan Shows Promise in HER2-Low Breast Cancer
Trastuzumab deruxtecan outperforms chemotherapy in HER2-low metastatic breast cancer clinical trial.
Breakthrough Combo Therapy Extends Survival in Aggressive Thyroid Cancer
Novel combination therapy shows promise for anaplastic thyroid carcinoma, significantly improving survival.
Shining Light on Relief: Photodynamic Therapy Shows Promise for Oral Mucositis in Cancer Patients
Study reveals photodynamic therapy's potential in reducing oral mucositis severity for cancer patients.
New Hope for BTK Inhibitor Intolerant Patients: Pirtobrutinib Shows Promise in B-Cell Malignancies
Pirtobrutinib demonstrates efficacy and tolerability in patients with B-cell cancers who couldn't tolerate other BTKis.